Inhibikase Therapeutics IncNASDAQ:IKT
- LAST PRICE2.2599
- TODAY'S CHANGE (%)0.2499 (12.4328%)
- Bid / Lots2.2500/ 1
- Ask / Lots2.2900/ 1
- Open / Previous Close2.0200 / 2.0100
- Day Range
- 52 Week Range
- Volume157,079
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IKT |
|---|---|---|
| 09:32 ET | 2502 | 2.005 |
| 09:35 ET | 3644 | 2 |
| 09:39 ET | 500 | 2 |
| 09:42 ET | 100 | 1.99 |
| 09:46 ET | 3233 | 2.02 |
| 09:48 ET | 1842 | 2 |
| 09:50 ET | 443 | 1.995 |
| 09:51 ET | 500 | 2 |
| 10:00 ET | 1600 | 1.99 |
| 10:02 ET | 1966 | 2 |
| 10:06 ET | 500 | 1.99 |
| 10:08 ET | 700 | 1.99 |
| 10:09 ET | 100 | 2.03 |
| 10:11 ET | 1000 | 2.04 |
| 10:18 ET | 3844 | 2.01 |
| 10:20 ET | 6000 | 2 |
| 10:22 ET | 100 | 2.01 |
| 10:26 ET | 300 | 2.0543 |
| 10:27 ET | 9818 | 1.98 |
| 10:29 ET | 100 | 2.0314 |
| 10:31 ET | 200 | 1.96 |
| 10:33 ET | 300 | 1.995 |
| 10:36 ET | 100 | 1.98 |
| 10:45 ET | 1000 | 2.03 |
| 10:47 ET | 8977 | 2.03 |
| 10:56 ET | 300 | 2.01 |
| 11:03 ET | 2086 | 2 |
| 11:07 ET | 704 | 1.98 |
| 11:21 ET | 1000 | 2.03 |
| 11:23 ET | 100 | 2.0275 |
| 11:27 ET | 1501 | 2.01 |
| 11:30 ET | 200 | 2 |
| 11:34 ET | 6185 | 2.01 |
| 11:36 ET | 2773 | 2.03 |
| 11:38 ET | 1919 | 2 |
| 11:39 ET | 2915 | 2.0043 |
| 11:45 ET | 145 | 2.02 |
| 11:48 ET | 500 | 2.03 |
| 11:50 ET | 200 | 2.03 |
| 11:52 ET | 100 | 2.035 |
| 11:54 ET | 100 | 2.05 |
| 11:57 ET | 2590 | 2.05 |
| 12:03 ET | 100 | 2.04 |
| 12:14 ET | 4000 | 2.07 |
| 12:17 ET | 690 | 2.0917 |
| 12:26 ET | 100 | 2.075 |
| 12:33 ET | 100 | 2.075 |
| 12:35 ET | 100 | 2.08 |
| 12:37 ET | 300 | 2.0935 |
| 12:39 ET | 7309 | 2.1 |
| 12:42 ET | 5950 | 2.11 |
| 12:44 ET | 1350 | 2.129 |
| 12:46 ET | 11991 | 2.14 |
| 12:48 ET | 2813 | 2.12 |
| 12:50 ET | 480 | 2.11 |
| 12:51 ET | 146 | 2.11 |
| 12:53 ET | 100 | 2.11 |
| 12:55 ET | 143 | 2.1 |
| 01:00 ET | 335 | 2.1481 |
| 01:02 ET | 3638 | 2.155 |
| 01:04 ET | 400 | 2.215 |
| 01:06 ET | 2600 | 2.22 |
| 01:08 ET | 200 | 2.22 |
| 01:11 ET | 1001 | 2.22 |
| 01:13 ET | 801 | 2.25 |
| 01:15 ET | 300 | 2.205 |
| 01:20 ET | 1424 | 2.37 |
| 01:22 ET | 3100 | 2.3 |
| 01:24 ET | 200 | 2.32 |
| 01:26 ET | 300 | 2.25 |
| 01:27 ET | 1100 | 2.3 |
| 01:33 ET | 1300 | 2.3871 |
| 01:38 ET | 100 | 2.26 |
| 01:40 ET | 1400 | 2.295 |
| 01:42 ET | 1600 | 2.2952 |
| 01:44 ET | 150 | 2.3652 |
| 01:49 ET | 1200 | 2.28 |
| 01:51 ET | 400 | 2.29 |
| 02:00 ET | 100 | 2.29 |
| 02:02 ET | 1136 | 2.2853 |
| 02:07 ET | 300 | 2.282 |
| 02:14 ET | 300 | 2.27 |
| 02:16 ET | 700 | 2.28 |
| 02:20 ET | 200 | 2.2896 |
| 02:21 ET | 1214 | 2.26 |
| 02:23 ET | 200 | 2.26 |
| 02:25 ET | 100 | 2.27 |
| 02:27 ET | 200 | 2.27 |
| 02:32 ET | 100 | 2.26 |
| 02:36 ET | 5100 | 2.2599 |
Nov 14, 2024
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity, from 8:37AM ET on Thursday Nov 14, 2024 by Dow Jones
8:37AM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity, from 8:37AM ET on Thursday Nov 14, 2024 by Dow Jones
8:37AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 8, 2024
DJ Inhibikase Therapeutics Initiated at Buy by Jefferies, from 7:24AM ET on Friday Nov 08, 2024 by Dow Jones
7:24AM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inhibikase Therapeutics Inc | 135.1M | -0.8x | --- |
Candel Therapeutics Inc | 132.7M | -2.9x | --- |
Black Diamond Therapeutics Inc | 137.5M | -1.8x | --- |
Acumen Pharmaceuticals Inc | 138.8M | -1.7x | --- |
PepGen Inc | 140.8M | -1.5x | --- |
TuHURA Biosciences Inc | 140.8M | -0.3x | --- |
Company Information
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Contact Information
- Headquarters
- 3350 Riverwood Parkway Se, Suite 1900ATLANTA, GA, United States 30339
- Phone
- 678-392-3419
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Roberto Bellini
- President, Chief Executive Officer, Director
- Milton Werner
- Chief Financial Officer
- Garth Lees-Rolfe
- Director
- David Canner
- Director
- Arvind Kush
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $135.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 67.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.05 |
EPS | $-2.72 |
Book Value | $1.77 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
